While generative AI has dominated the spotlight in the past year, machine learning programs have already been significantly impacting patients and physicians for several years. The question now arises: how will the emergence of programs like ChatGPT, coupled with increasing calls to scrutinize their safety, influence the adoption of new AI programs and diagnostics in healthcare?  

This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. 

To learn more about the topics in this episode: 
2024 forecast: Will generative AI find what it needs to deliver for patients?
FDA to form advisory committee for digital health and AI
US government to launch AI Safety Institute, develop standards for biotech R&D
Biden to sign sweeping executive order pursuing 'safe, secure and trustworthy' AI development

While generative AI has dominated the spotlight in the past year, machine learning programs have already been significantly impacting patients and physicians for several years. The question now arises: how will the emergence of programs like ChatGPT, coupled with increasing calls to scrutinize their safety, influence the adoption of new AI programs and diagnostics in healthcare?  
This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/medtech/2024-forecast-will-generative-ai-find-what-it-needs-deliver-patients" data-cke-saved-href="https://www.fiercebiotech.com/medtech/2024-forecast-will-generative-ai-find-what-it-needs-deliver-patients">2024 forecast: Will generative AI find what it needs to deliver for patients?</a> </li>
<li><a href="https://www.fiercebiotech.com/medtech/fda-form-advisory-committee-digital-health-and-ai" data-cke-saved-href="https://www.fiercebiotech.com/medtech/fda-form-advisory-committee-digital-health-and-ai">FDA to form advisory committee for digital health and AI</a> </li>
<li><a href="https://www.fiercebiotech.com/medtech/us-government-launch-ai-safety-institute-develop-standards-biotech-rd" data-cke-saved-href="https://www.fiercebiotech.com/medtech/us-government-launch-ai-safety-institute-develop-standards-biotech-rd">US government to launch AI Safety Institute, develop standards for biotech R&amp;D</a> </li>
<li><a href="https://www.fiercehealthcare.com/ai-and-machine-learning/biden-sign-sweeping-executive-order-pursuing-safe-secure-and-trustworthy-ai" data-cke-saved-href="https://www.fiercehealthcare.com/ai-and-machine-learning/biden-sign-sweeping-executive-order-pursuing-safe-secure-and-trustworthy-ai">Biden to sign sweeping executive order pursuing 'safe, secure and trustworthy' AI development</a> </li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement